Full Text View
Tabular View
No Study Results Posted
Related Studies
CVD Risk and Health in Postmenopausal Phytoestrogen Users
This study has been completed.
Study NCT00000613   Information provided by National Heart, Lung, and Blood Institute (NHLBI)
First Received: October 27, 1999   Last Updated: January 3, 2006   History of Changes

October 27, 1999
January 3, 2006
April 1997
 
 
 
Complete list of historical versions of study NCT00000613 on ClinicalTrials.gov Archive Site
 
 
 
CVD Risk and Health in Postmenopausal Phytoestrogen Users
 

To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.

BACKGROUND:

Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of life in postmenopausal women through use of a dietary supplement of phytoestrogen.

DESIGN NARRATIVE:

Randomized, double-blind, placebo-controlled study. A total of 210 women were enrolled in the study to be followed for one to two years. The women were randomized to phytoestrogen treatment or to placebo. Data are collected at baseline visits, at one and three month follow-up telephone calls, and at 6, 12, and 24 month follow-up clinic visits. Measures of high density lipoprotein and other heart disease risk factors, hip and spine bone density, and depression, life satisfaction, and quality of well-being are obtained. Cross-sectional and longitudinal comparisons of treatment and placebo groups are performed before and after adjustment and stratification for potentially confounding covariates.

The study was renewed in March 2002 to assess whether the women treated with phytoestrogens had lowered homocysteine, interleukin-6, C-reactive protein, E-selectin, and decreased obesity and fat mass over two years.

Phase II
Interventional
Prevention, Randomized, Double-Blind, Placebo Control
  • Bone Diseases
  • Cardiovascular Diseases
  • Coronary Disease
  • Depression
  • Heart Diseases
  • Myocardial Ischemia
  • Osteoporosis
  • Postmenopause
  • Behavioral: dietary supplements
  • Drug: genistein
  • Behavioral: diet, soy proteins
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
December 2004
 

Postmenopausal women, ages 45 to 74.

Female
45 Years to 74 Years
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00000613
 
116
National Heart, Lung, and Blood Institute (NHLBI)
 
Investigator: Donna Kritz-Silverstein University of California, San Diego
National Heart, Lung, and Blood Institute (NHLBI)
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP